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The sodium-iodine symporter (NIS) is expressed on the cell membrane of many thyroid cancer cells, and is responsible for the
radioactive iodine accumulation. However, treatment of anaplastic thyroid cancer is ineﬀective due to the low expression of NIS
on cell membranes of these tumor cells. Human embryonic stem cells (ESCs) provide a potential vehicle to study the mechanisms
of NIS expression regulation during diﬀerentiation. Human ESCs were maintained on feeder-independent culture conditions.
RT-qPCR and immunocytochemistry were used to study diﬀerentiation marker expression, 125Iu p t a k et os t u d yN I Sf u n c t i o n .W e
d e s i g n e dat w o - s t e pp r o t o c o lf o rh u m a nE S Cd i ﬀerentiation into thyroid-like cells, as was previously done for mouse embryonic
stem cells. First, we obtained deﬁnitive endoderm from human ESCs. Second, we directed diﬀerentiation of deﬁnitive endoderm
cells into thyroid-like cells using various factors, with thyroid stimulating hormone (TSH) as the main diﬀerentiating factor.
Expression of pluripotency, endoderm and thyroid markers and 125I uptake were monitored throughout the diﬀerentiation steps.
These approaches did not result in eﬃcient induction of thyroid-like cells. We conclude that diﬀerentiation of human ESCs into
thyroidcellscannotbeinducedbyTSHmediasupplementationaloneandmostlikelyinvolvescomplicateddevelopmentalpatterns
that are yet to be understood.
1.Background
Human ESCs are the subject of extremely intensive research
nowadays. ESCs possess the ability to diﬀerentiate into all
cell types, and further form all tissues of the body. This
unique feature makes these cells a valuable source for in
vitro formation of diﬀerentiated cells which can be used
in clinical applications, mostly in substitutive therapy [1].
Embryonic stem cells can also provide an important tool
for developmental biology studies. This is especially true for
human embryo development studies, where few approved
human ESC lines can be used for the research and numerous
ethical issues exist [2, 3].
Diﬀerentiation of ES cells to thyroid cells has been
proposed as an approach to study thyroid gland develop-
ment where mechanisms still remain unclear; especially
concerning the early development stages [4, 5]. Human ES
cells possess considerable self-renewing potential and could,
in theory, provide an unlimited source of derived thyroid
cells. Such substitutive therapy may have clinical application
in diseases such as congenital hypothyroidism, thyroid
cancer, and acquired hypothyroidism from autoimmune
thyroiditis [4, 5].
Thyroid tissue cells originate from all three embryonic
germ layers. The stroma of the thyroid gland develops
from mesoderm; parafollicular cells (C-cells), representing
calcitonin secreting tissue within the thyroid gland, originate
from neural crest (derivative of ectoderm); and thyroid
follicular cells, the most abundant cellular population,
are from endodermal origin. Follicular cells possess the
unique ability to absorb and concentrate molecular iodine,
the crucial element of thyroid hormones (triiodothyronine2 Stem Cells International
[T3] and thyroxine [T4]). This phenomenon provides the
molecular mechanism for diagnostics and treatment of the
variety of thyroid gland diseases with radioactive iodine
isotopes, mostly with 131I.
We implemented an approach where human ESCs were
used as a model for studying the mechanisms of NIS
maturation during their diﬀerentiation to thyroid follicular
cells. Dediﬀerentiation takes place in cancer cells, and it
is especially prominent in high-grade tumors. Therefore,
studying the reverse process, diﬀerentiation, may reveal the
patterns of NIS expression regulation. This knowledge may
provide alternative ideas of NIS induction in cancer cells and
could open new possibilities for radioisotope treatment of
thyroid cancer.
Previous studies on mouse ESCs demonstrated their suc-
cessful diﬀerentiation into thyroid cells with thyroid stim-
ulating hormone (TSH) as the main diﬀerentiating factor
[5, 6]. We tested various approaches to produce thyroid
follicular cells from human ESCs including that used for
diﬀerentiation of mouse ESCs. We used both a one step
protocol(directdiﬀerentiationfromhumanESCstothyroid-
like cells) and a two-step protocol through endoderm for-
mation. However, our attempts did not result in an eﬃcient
induction of thyroid follicular cells. We attributed this to
the diﬀerences in the diﬀerentiation patterns in mice and
humans [7]. Therefore, we believe that diﬀerentiation of
human ESCs into functional thyroid follicular cells requires
diﬀerent in vitro approaches that are yet to be revealed.
2. Methods
2.1. Cell Lines and Cell Culture. Human ESCs (H9 cell line,
WiCell, Madison, WI, passage 35–40) were maintained on
feeder-independent culture conditions, using BD Matrigel
humanESC-qualiﬁedMatrix(BDBiosciences,SanJose,CA),
and grown in mTeSR-1 (Stemcell Technologies, Vancouver,
Canada) at 37◦C and 5% CO2.C e l lc u l t u r e sw e r em a i n -
tained and expanded according to manufacturer’s protocol.
Medium was changed every day and cells were passaged
using Collagenase IV (Invitrogen, Carlsbad, CA) every 6-
7 days. During cell passaging only phenotypically uniform
pluripotent human ESC colonies were collected. In all
our experiments, we did not allow cell to go above 70%
conﬂuence (this concerns cells grow as a single layer). The
human ESCs were allowed to grow in colonies such that they
did not form multiple layers and did not touch each other.
2.2. Directed Diﬀerentiation of hESC into Deﬁnitive Endo-
derm. H9 human ESCs were seeded onto 6-well plates
covered with BD Matrigel human ESC-qualiﬁed Matrix (BD
Biosciences) at 105 cells per well. Then, the cells were main-
t a i n e di nm T e S R 1m e d i u ma t5 %C O 2 and 37◦C for two days
with medium changed each day. Starting from day 3, cells in
culture were maintained in diﬀerentiation media: Protocol 1,
DMEM/F12 (Stemcell Technologies) supplemented with 5%
KSR(knockoutserumreplacement)(Invitrogen),100ng/mL
Activin A (Stemcell Technologies), 4ng/mL bFGF), [8],
and Protocol 2, DMEM/F12 supplemented with 20% KSR,
100ng/mL Activin A, 4ng/mL bFGF, and 20µM LY294002
(Cayman Chemical Company, Ann Arbor, MI) [9].
The diﬀerentiation medium was changed every day [9].
On the 4th day of diﬀerentiation cells were trypsinized and
collected for further studies.
2.3. Embryoid Body Formation. After 5 days human ESC
coloniesweretransferredtoultra-lowattachmentTx25ﬂasks
(Corning, Corning, NY) and maintained in embryoid body
(EB) media, consisting of DMEM/F12 (Stemcell Technolo-
gies) plus 15% KSR and 5% KFBS (knockout fetal bovine
serum), which was changed every 48 hours. We incubated
these cells for 5 days at 5% CO2 and 37◦Ct oa l l o wE B st o
form.
2.4. Directed Diﬀerentiation to Thyroid Line. Successful thy-
roid diﬀerentiation has been shown with mouse ESCs [5, 6].
We used the mouse ESCs protocol based on TSH stim-
ulation. The following precursor cells were used for thy-
roid diﬀerentiation—human ESCs, embryoid bodies, and
deﬁnitive endoderm cells (derived from the two protocols
described previously). Cells were maintained in either of
three types of thyroid diﬀerentiation media: (1) DMEM/F12
supplemented with 20% KSR, 100mcU/mL human recom-
binant TSH (Fitzerald Industries international, Concord,
MA): (2) DMEM/F12 supplemented with 5% FBS, 1mU/mL
bovine TSH (Sigma, St. Louis, MO): (3) DMEM/F12 sup-
plemented with 5% FBS, 1mU/mL bovine TSH, 10mcg/mL
human insulin (Gibco, Grand Island, NY), 6mcg/mL trans-
ferrin (Invitrogen), 10−8M hydrocortisone (Calbiochem,
Gibbstown, NJ).
On days 5, 14, and 21 cells were collected for thyroid
marker expression analysis.
2.5. Quantitative RT-PCR. Cells were trypsinized, washed
two times with PBS, and suspended in PBS with a con-
centration 10,000 cells per 1µL. cDNA was synthesized
using SuperScript III Cells Direct cDNA System (Invitrogen)
according to manufacturer’s recommendations. Quantitative
real-timePCR(qPCR)wasperformedoniCycleriQmachine
(Bio-Rad, Hercules, CA) using SYBR GreenER qPCR Super-
Mix for iCycler (Invitrogen). Primers were purchased from
Qiagen (Valencia, CA). PCR protocol consisted of 50◦Cf o r
2min, 95◦C for 10min, followed by 50 cycles (95◦C, 15
seconds, 55◦C, 30 seconds, 72◦C, 30 seconds) according
to Quantitect Primer Assay recommendations. Ct (cycle
threshold) values were obtained for each sample, averaged
over triplicates, and normalized to beta-actin, according to
the formula E = 2Ct [beta−actin]−Ct [studied gene],w h e r eE is a
normalized expression of studied gene, Ct (beta-actin) and
Ct (studied gene) are Ct values of beta-actin and studied
gene in corresponding samples. Normal human thyroid
tissue (obtained from Laboratory of Pathology for Human
Biological Materials, NIH) was used as positive control
for quantitative RT-PCR. RNA was isolated from tissue
with RNAqueous-4PCR kit (Ambion, Austin TX) according
to manufacturer’s recommendations. Obtained mRNA was
converted to cDNA and processed by PCR in the sameStem Cells International 3
manneraswithculturedcells(seeabove).PCRproductswere
run on 6% precast native polyacrylamide TBE gels (Invitro-
gen) and stained with Ethidium Bromide (Invitrogen). DNA
ladder (MassRuler, DNA Ladder Low Range, Invitrogen) was
run as well and the gel images corresponding to the positions
o ft h ef r a g m e n t sw i t ha m p l i c o nl e n g t ho fe x p e c t e dP C R -
products were cut and presented.
2.6. Immunocytochemistry. For immunohistochemistry cells
were grown on glass-bottom LabTek two-well Cham-
ber Slide (BD Biosciences) in the feeder-free conditions
d e s c r i b e dp r e v i o u s l y .T h ec e l lc u l t u r e sw e r eﬁ x e dw i t h4 %
paraformaldehyde for 10 minutes and then permeabilized
with 0.1% Triton-X-100 in phosphate-buﬀered saline (PBS)
for 5 minutes. Primary mouse antibodies were applied
for 1 hour, and appropriately goat anti-mouse DyLight
649 labeled secondary antibodies (Abcam, Cambridge, MA)
were used for 1 hour. All secondary antibodies were tested
for nonspeciﬁc immunoreactivity. The following primary
antibodies were used: TSHR, TPO, and NIS (Abcam). DAPI
stain was used to identify the cell nuclei. After mounting
in antifade media (VectaShield, Vector Laboratories, Inc.,
Burlingame, CA), the samples were examined by Axioplan
Zeiss epiﬂuorescent microscope (Carl Zeiss, Thornwood,
NY). The camera exposure time and microscope settings
were kept constant across all corresponding samples.
2.7. Iodine-125 Uptake Studies. Uptake of 125I was measured
as previously described [10]. Brieﬂy, cells were cultured in
diﬀerentiationmedium;afteraspirating theculturemedium,
the cells were washed with 1mL of Hank’s balanced salt
solution (HBSS) (Grocell, Manassas, VA). 125I uptake was
initiated by adding to each well 500µLb u ﬀered HBSS
containing 0.1µCi carrier-free Na125Ia n d1 0 µMN a It o
obtain a speciﬁc activity of 20mCi/mmol. After 1 hour at
37◦C in a humid atmosphere, the radioactive medium was
aspirated and cells were washed with 1mL of ice-cold HBSS.
Cells were detached by cell scraper. One mL of 95% ethanol
was added to each well for 20min and then transferred into
vialsforcounting witha gammacounter(Biotracers,Fairfax,
VA). Iodide uptake was expressed as decay per minute (dpm)
per cell.
3. Results
3.1. Design of Diﬀerentiation Protocols. To achieve the diﬀer-
entiation of human ESCs to thyroid cells, we tried several
approaches. We started with the design previously used for
diﬀerentiation of mouse ESCs into thyroid cells [5, 6]. In
these studies, Arufe et al. used TSH as a main diﬀerentiating
factor. At the same time, leukemia-inhibiting factor (LIF),
an essential component to maintain pluripotency of mouse
embryonic stem cells, was removed from the medium. To
obtain murine endodermal cells, they produced EBs prior to
TSH stimulation. We designed modiﬁed one-step and two-
step diﬀerentiation protocols for our human ESCs. First,
we decided to stimulate human ESCs with TSH avoiding
endoderm formation, as it was shown that in some cases,
this simple approach allows for the diﬀerentiation of ESCs,
for example, into osteocytes [11]. Next, we tried several
approaches to obtain endodermal cells prior to stimulation
with TSH. EB formation and directed diﬀerentiation to
deﬁnitive endoderm were performed. Our detailed protocols
are listed in Section 2. A schematic presentation of these
diﬀerentiation strategies is shown in Figure 1.
3.2. Embryoid Body Formation. To obtain a source of endo-
derm cells for diﬀerentiation to thyroid cells, we formed
EBs from human ESCs. EBs are three-dimensional spheroid
cellular complexes, which are formed when colonies of
embryonic stem cells are detached from the culture plate
surface and allowed to ﬂoat in the culture medium. Another
important requirement for EB formation is that culture
medium should be depleted of essential factors for maintain-
ing the pluripotency of ESCs. For mouse ESCs, the essential
factor is LIF, while bFGF and multiple factors produced
by mouse embryonic ﬁbroblasts (MEFs) or sold in a
proprietary formulation by companies (like Stem Cells, etc.)
are essential for human ESCs. Formation and morphology
of EBs have been well described and their morphology was
characterized in the literature [12–14]. EBs derived from
human ESCs are usually allowed to grow 5–10 days, so that
they become bigger in size and cell number. At this time, the
morphology of formed cell complexes should be similar to
the gastrulation stage of the embryo; that is, cells of three
germ layers (ectoderm, mesoderm, and endoderm) should
bepresent.Cellsatthisstageareoftenusedfordiﬀerentiation
to more mature cell types.
We formed EBs from colonies of human ESCs by allow-
ing EBs to grow in medium that was depleted of any
essential factors for 5 days (detailed protocol can be found in
Section 2). Pictures of obtained EBs are shown in Figure 2.
Using quantitative RT-PCR, we next measured gene expres-
sion in cells from the EBs. Positive gene markers represent
early diﬀerentiation markers of all three germ layers, as
well as pluripotency markers (see Table 1). The results of
gene-expression studies are shown in Figure 3.A sc a nb e
seen EBs express markers of all three germ layers. It is
interesting to note that expression of OCT3 and NANOG
is preserved. SOX17 and FOXA2 signaling for endoderm are
noticeably expressed on the 5th day of EB formation, which
makes cells derived from EBs a reasonable source for further
diﬀerentiation to endoderm derivatives.
3.3. Directed Diﬀerentiation of Human ESCs to Deﬁnitive
Endoderm. To obtain a cell population with a high concen-
tration of endoderm cells, we used protocols for directed
diﬀerentiation of human ESCs to deﬁnitive endoderm.
Two protocols from recent studies were tested. In the ﬁrst
approach, [8] Activin A (100ng/mL) and human b-FGF
(4ng/mL) was used as the main diﬀerentiating factors. In the
second protocol, [9] an inhibitor of PI3 kinase, LY294002, in
combination with Activin A (100ng/mL) and human b-FGF
(4ng/mL) were used. According to other authors, this last
approach provides a much higher endoderm yield [9]. How-
ever,certainconcernsaboutthediﬀerentiationcapabilitiesof4 Stem Cells International
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Figure 1: Proposed patterns of directed diﬀerentiation of human embryonic stem cells to thyroid cell line.
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Figure 2: Embryoid body formation. Embryoid bodies tend to form structures similar to those seen in normal embryonic development
(yolk sac, amniotic sac, etc.). The embryoid bodies vary in shape, size, and density.Stem Cells International 5
Table 1: Markers and their description indicating pluripotency, three germ layers, and thyroid tissue.
Pluripotency Ability to give rise to all tissues of the body Oct3/4 POU class 5 homeobox 1
Nanog Nanog homeobox
Ectoderm Nervous system, neural crest and its derivatives, epidermis,
eye, salivary, and skin glands
PAX6 Paired box 6
SOX1 SRY-box 1
Mesoendoderm Gives rise to mesoderm and endoderm T T, brachyury homolog
Mesoderm Connective tissue, muscles, reproductive system, spleen,
peritoneum, urinary system, mesothelium, heart
TBX6 T-box 6
KDR kinase insert domain receptor
Deﬁnitive endoderm Digestive and respiratory tracts, endocrine glands, and
organs such as the liver and pancreas
SOX17 SRY-box 17
FOXA2 Forkhead box A2
Thyroid tissue Thyrocytes within thyroid gland derived from deﬁnitive
endoderm
TSHR Receptor to TSH
TPO Thyroperoxidase
NIS Sodium-iodine symporter
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Figure 3: Expression of pluripotency and early diﬀerentiation
mRNA markers in EBs and pluripotency markers in H9 hESCs on
the right. Detailed marker description is presented in Table 1.
derivedcellsexisted.Weperformedageneexpressionassayto
study pluripotency markers (OCT3, NANOG) and deﬁnitive
endoderm markers (SOX17, FOXA2). The results for both
protocols are presented in Figure 4. After 4 days of directed
diﬀerentiation to deﬁnitive endoderm, the expression of
pluripotency markers went down (Figure 4(a)), and the
expression of endodermal markers increased (Figure 4(b)).
In addition, the protocol implementing LY294002 appeared
to be the most eﬃcient.
3.4. Directed Diﬀerentiation to Thyroid-Like Cells. After ob-
taining deﬁnitive endoderm cells, we proceeded with
directed diﬀerentiation to thyroid follicular cells. The fol-
lowing cell sources were used: human ESCs, EBs, and cells
d e r i v e df r o md i r e c t e dd i ﬀerentiation to deﬁnitive endoderm
with two protocols. Although for directed diﬀerentiation to
any mature cell line it is recommended to perform step-
by-step diﬀerentiation (i.e., germ layer-organ speciﬁc–tissue
speciﬁc), we attempted to perform direct diﬀerentiation
from human ESCs to thyroid follicular cells as well. TSH was
used as a main diﬀerentiating factor because of the success
of this approach for the diﬀerentiation of mouse ESC [5, 6].
Time points of 5, 14, and 21 days were chosen. First we
incubated cells with 100 mcU/mL of TSH. The following
thyroid-speciﬁcmarkerswereused:TSHR(receptortoTSH),
TPO(thyroperoxidase)andNIS(sodium-iodinesymporter).
As a positive control for quantitative RT-PCR, we used
normal human thyroid tissue, which revealed expressions
of all studied thyroid markers. However, expression of
thyroid markers was not observed at any time point in
the diﬀerentiation for all protocols tested (Figure 5). It is
interesting to note that although we did not ﬁnd speciﬁc
bands corresponding to thyroid markers after performing
gel-electrophoresis of RT-PCR products, on the 21st day of
diﬀerentiation in cells derived from both endoderm sources
for TSHR and NIS markers, we observed PCR products
of diﬀerent than expected lengths. The origin of these
fragments is unclear yet and will be a subject of further
investigation.
It is known that it is extremely hard to culture nor-
mal thyroid follicular cells; they survive few passages and
phenotypically degrade in culture [15]. In light of this,
Penna-Martinez et al. [15] suggested a protocol allowing
comparatively prolonged cultivation of thyroid cells in
culture obtained from ﬁne needle aspiration biopsy (FNAB).
They found a combination of deﬁned factors that makes
it possible to culture thyroid cells for up to 3 weeks with
simultaneous preservation of their morphological and func-
tional characteristics. We implemented the same strategy in
our experiments adding the combination of factors to the
media, as recommended by Penna-Martinez et al. [15]. As
before, human ESCs, EB cells, and endodermal cells were
used for diﬀerentiation. However, we still were unable to
see any signiﬁcant expression of thyroid markers along the
diﬀerentiation pathway with this modiﬁed protocol.
Additionally, we performed immunocytochemistry stud-
ies with cells on the 21st day of directed thyroid diﬀerenti-
ation. We assumed that a small population of derived cells
might possess thyroid features. However, none of the tested
markers(TSHR,TPO,NIS)appearedtobepositive (datanot
shown).6 Stem Cells International
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Figure 4: Expression of pluripotency (a) and deﬁnitive endoderm (b) mRNA markers at directed endoderm diﬀerentiation. Human ESCs
were diﬀerentiated using two protocols described in Section 2. Detailed marker description is presented in Table 1.
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Figure 5: PCR results for thyroid markers expression in derived
cells under diﬀerent protocols and normal human thyroid tissue.
3.5. 125I Uptake Studies. We performed a functional assay to
establish the ability of diﬀerentiated cells to take up iodine.
Even though we could not detect a signiﬁcant expression of
thesodium-iodinesymporter,weproceededwithradioactive
iodine studies as a sensitive functional assay. We incubated
cells with a mixture of radioactive and cold iodine according
to a well-established protocol [10] and measured intracellu-
lar 125I with gamma-counter after 1 hour of incubation. We
measured iodine uptake in “thyroid like” cells derived from
thediﬀerentstudiedprotocols;however,wedidnotobservea
statistically signiﬁcant increase in radioiodine uptake under
any of these experimental conditions.
4. Discussion
The sodium iodine symporter has been an important subject
of nuclear medicine research for decades, because it serves
as an eﬀector for cell-localized radiation therapy due to its
unique ability to concentrate iodine inside a cell. Iodine-
131 radiotherapy in clinical practice causes the results
of thyroid cancer treatment to improve dramatically. But
severalimportantissuesstillneedtoberesolved,forexample,
the treatment of anaplastic thyroid cancer, which lacks NIS
expression in its cellular membranes. Also, other tissues
like mammary glands are known to express low levels of
NIS [16–18] ,w h i c hp o t e n t i a l l yc o u l db eu s e df o rb r e a s t
cancer treatment [18–23]. A better understanding of the
appearance of NIS during embryologic development may
help to explain why fetuses of children are so sensitive
to medical and environmental radioactive exposures. The
structure of NIS and its regulation are well studied, and
numerous approaches to induce or improve its functioning
have been proposed from gene transfection [18, 24–26]t o
pharmacological induction [27]. However, many of them
lack the potential for clinical translation. The hypothesis we
proposed used human embryonic stem cells as a model for
studying NIS maturation at diﬀerent stages of diﬀerentiation
towards thyroid follicular cells. This approach might provide
insight into the mechanism of NIS regulation in cancer
dediﬀerentiation which is opposite in its apparent expression
of NIS.
In this study, we attempted to develop the protocol
for directed diﬀerentiation of human ESCs to thyroid cells.
A similar approach has been successfully used by Arufe
et al. [5] in mouse ESCs. They obtained “thyroid-like
cells” possessing features of thyroid cells. The derived cells
expressed main thyroid markers (TSHR, NIS, TPO, TG,
PAX8) determined by RT-PCR and western blot. Arufe et
al. [5] proposed a two-step protocol for mouse ESCs: and
Step 1, obtaining endoderm cells through generation of EBs;
Step 2, stimulation of EB cells by TSH to derive thyroid
cells. In our study, we used a similar approach; in addition,
several modiﬁcations and variations were implemented. We
used H9 human embryonic stem cell line as one of the
most studied cell lines and proved to be a good source
for successful diﬀerentiation to variety of cell types In ourStem Cells International 7
experiments, we were able to obtain human endoderm cells
using three diﬀerent protocols: (1) using EB formation as in
the mouse ESCs study described above: (2) using deﬁnitive
factors (Activin A, bFGF), and (3) LY294002, PI3-kinase
(phosphoinositide3-kinase)inhibitorfordirectedendoderm
formation [8, 9].
However, concerns exist regarding the potential of de-
rived endoderm cells to form more specialized and mature
cell types when these protocols are used; especially with
LY294002 as PI3-kinase participates in many pathways and
its inhibition may aﬀect diﬀerentiation abilities of the cells.
Nevertheless, several studies showed successful diﬀerentia-
tion of endodermal cells into liver [28–30], pancreatic, and
lung cells [30, 31]. We used endoderm cell derived from all
three protocols for further diﬀerentiation into the thyroid
line. TSH was used as a main diﬀerentiation factor. Since
gestation period is longer in humans compared to mice, we
allowed cells to grow longer (up to 21 days). We also varied
the concentration of TSH and did not observe any clear
expression of thyroid markers in any of the group of cells.
A possible explanation for the absence of observable thyroid
markers was that cells might diﬀerentiate to thyroid cells but
couldnotsurviveinthecultureconditions.Wethenacquired
the previously proposed protocol for culturing of thyroid
cells obtained from a ﬁne needle aspiration biopsy [15].
This protocol maintained thyroid cells in culture up for to
3 weeks. However, adding essential factors from this protocol
to our diﬀerentiation media did not result in the formation
of cells possessing thyroid features. We also measured iodine
uptakebycellsderivedwithdiﬀerentprotocolsusing 125I.We
did not see any changes between control and experimental
cells.
We think that even though diﬀerentiation pathways in
mice and humans might possess similar features, many
molecular mechanisms may vary. This also concerns source
cells used for diﬀerentiation. Even though it is claimed
that mouse ESCs used by Arufe et al. [5, 6] and H9 cells
were taken from inner cell mass of blastocysts, concerns
may arise about the terms of blastocyst stage as in early
embryogenesis cells diﬀerentiate and maturate extremely
fast, such that mere hours may matter. Also it was shown
[32] that even within one species ESCs might vary in their
biological properties, namely, in their ability to diﬀerentiate
to various tissues, if they belong to diﬀerent cell lines, or
if they are of diﬀerent passages even within the same cell
line. Besides, there is another important point which might
explain observed diﬀerences. In experiments with mouse
ESCs [5, 6] and in our experiments along the diﬀerentiation
cells were growing as a monolayer (on Matrigel for human
ESCs). It is possible that 2D geometry can be appropriate
for diﬀerentiation towards thyroid line for mouse ESCs,
while for human ESCs spatial orientation of cells might
be a strong requirement even if stimulation with essential
factors is correct. In this case 3D cell culture method must be
attempted. One of the limitations of this study is using only
one human embryonic cell line, H9. Even though cells from
this cell line were successfullydiﬀerentiated toward many cell
types, including endoderm derivatives, we still have to admit
that luck of diﬀerentiation to thyroid cells might be related
to peculiarities of H9 cell line, and thus, results may not gen-
eralizable to all human embryonic cell lines.
5. Conclusions
Based on the results of our experiments, we conclude that
diﬀerentiation of H9 human ESCs into thyroid cells cannot
be induced by TSH media supplementation alone and most
likely involves complicated developmental patterns that are
yet to be determined.
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